Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Post-polycythemia Vera (Post-PV) Myelofibrosis Clear all
Completed Phase 2 Interventional Results available

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

NCT04629508
View directory record Official record
Conditions
Myelofibrosis, Polycythemia Vera, Thrombocythemia
Interventions
itacitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
New Orleans, Louisiana • Bethesda, Maryland • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

NCT02101268
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions
Momelotinib, Best Available Therapy (BAT)
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Jul 23, 2026, 10:13 AM EDT
Recruiting Phase 2 Interventional

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

NCT05835466
View directory record Official record
Conditions
Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Interventions
reparixin
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 10:13 AM EDT
Not listed Phase 1 Interventional

A Safety and Tolerability Study of Jaktinib

NCT05279001
View directory record Official record
Conditions
Myelofibrosis
Interventions
Jaktinib Hydrochloride Tablet
Drug
Lead sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Jul 23, 2026, 10:13 AM EDT
Withdrawn Phase 2 Interventional

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

NCT04054245
View directory record Official record
Conditions
Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
Interventions
LOXL2 Inhibitor PAT-1251, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Jul 23, 2026, 10:13 AM EDT
Terminated Phase 3 Interventional Results available

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

NCT03755518
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
FEDRATINIB
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Aurora, Colorado • Miami, Florida • Augusta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jul 23, 2026, 10:13 AM EDT
Not listed Phase 1Phase 2 Interventional

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

NCT04485260
View directory record Official record
Conditions
Myelofibrosis
Interventions
KRT-232, Ruxolitinib
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Duarte, California • Baltimore, Maryland • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

NCT00910728
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-Polycythaemia Vera, Essential Thrombocythaemia Myelofibrosis
Interventions
AZD1480
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
25 Years to 99 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

NCT02515630
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis, Postessential Thrombocythemia (Post-ET) Myelofibrosis
Interventions
MMB
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 23, 2026, 10:13 AM EDT
Terminated Phase 1 Interventional Results available

Anti-TGF-beta Therapy in Patients With Myelofibrosis

NCT01291784
View directory record Official record
Conditions
Myelofibrosis, Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Post-essential Thrombocythemia Related Myelofibrosis
Interventions
monoclonal antibody to TGF-beta
Biological
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Pomalidomide for Myelofibrosis Patients

NCT00946270
View directory record Official record
Conditions
Polycythemia Vera, Thrombocythemia
Interventions
CC-4047, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

NCT01732445
View directory record Official record
Conditions
Anemia, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
ruxolitinib phosphate, danazol, quality-of-life assessment, questionnaire administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Scottsdale, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Jul 23, 2026, 10:13 AM EDT
Terminated Phase 2 Interventional Results available

Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis

NCT00630994
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
Interventions
Dacogen
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT00935987
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Interventions
CYT387
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Jul 23, 2026, 10:13 AM EDT